Literature DB >> 7696183

Rak, a novel nuclear tyrosine kinase expressed in epithelial cells.

W G Cance1, R J Craven, M Bergman, L Xu, K Alitalo, E T Liu.   

Abstract

We have identified a new tyrosine kinase from human breast cancer cells called Rak (a Russian word for cancer) that shares 51% identity with c-Src. Sequencing of the full-length complementary DNA revealed that Rak is a tyrosine kinase with a molecular weight of 54,000 that contains SH2 and SH3 domains, as well as tyrosine residues analogous to the autophosphorylation and regulatory tyrosines of the Src family. Biochemical and site-directed mutagenesis analyses revealed that a carboxy-terminal peptide of p54rak was phosphorylated by a cytoplasmic tyrosine kinase (CSK) and that, as in the Src family, it is the COOH-terminal tyrosine that is phosphorylated by CSK. However, there were some properties of Rak that are distinct from Src-like kinases: (a) expression of Rak was predominantly in epithelial-derived cell lines and tissues, especially normal liver and kidney, and cell lines of breast and colon origin; (b) Rak does not harbor the NH2-terminal glycine essential for myristylation and membrane localization; and (c) Rak possesses a putative bipartite nuclear localization signal in the SH2 domain, and subcellular fractionation studies revealed that p54rak resides predominantly in the nucleus. In addition, p54rak was overexpressed in subsets of primary human epithelial tumors, suggesting that p54rak may have a role in human cancer. Thus, Rak is a novel epithelial-associated nuclear tyrosine kinase that may represent a unique subfamily of the Src-related kinases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7696183

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  19 in total

1.  Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine.

Authors:  Andrea Haegebarth; Wenjun Bie; Ruyan Yang; Susan E Crawford; Valeri Vasioukhin; Elaine Fuchs; Angela L Tyner
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 2.  [SRC kinases in tumor therapy].

Authors:  Wolfram Dempke; Roland Zippel
Journal:  Med Klin (Munich)       Date:  2010-10-28

3.  FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation.

Authors:  Lei Hua; Ming Zhu; Xu Song; Jun Wang; Zhen Fang; Chunting Zhang; Qiong Shi; Wenjian Zhan; Lei Wang; Qingming Meng; Xiuping Zhou; Rutong Yu
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

4.  A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation.

Authors:  V Vasioukhin; A L Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

Review 5.  Protein kinases in human breast cancer.

Authors:  W G Cance; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

Review 6.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

7.  FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin/β-catenin complex formation.

Authors:  Qiong Shi; Xu Song; Jun Wang; Jia Gu; Weijian Zhang; Jinxia Hu; Xiuping Zhou; Rutong Yu
Journal:  J Mol Neurosci       Date:  2014-06-27       Impact factor: 3.444

8.  Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak.

Authors:  Subhashini Chandrasekharan; Ting Hu Qiu; Nawal Alkharouf; Kelly Brantley; James B Mitchell; Edison T Liu
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

Review 9.  RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Cell Cycle       Date:  2009-09-29       Impact factor: 4.534

10.  The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity.

Authors:  Michael Welsh; Charlotte Welsh; Maria Ekman; Johan Dixelius; Robert Hägerkvist; Cecilia Annerén; Björn Akerblom; Siavosh Mahboobi; Subhashini Chandrasekharan; Edison T Liu
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.